新闻源 财富源

2019年10月16日 星期三

康缘药业(600557)公告正文

康缘药业:2012年第三季度报告

公告日期:2012-10-27

    股票简称:康缘药业                                  股票代码:600557
              江苏康缘药业股份有限公司
                     2012 年第三季度报告
                      二〇一二 年 十 月 二十五 日
      江苏康缘药业股份有限公司(股票代码:600557)                    2012 年第三季度报告
                                          目         录§1 重要提示 .......................................................................... 2§2 公司基本情况 ...................................................................... 2§3 重要事项 .......................................................................... 3§4 附录 .............................................................................. 5
      江苏康缘药业股份有限公司(股票代码:600557)                              2012 年第三季度报告§1 重要提示
    1.1 本公司董事会、监事会及其董事、监事、高级管理人员保证本报告所载资料不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
    1.2 公司全体董事出席董事会会议。
    1.3 公司第三季度财务报告未经审计。
    1.4
    公司负责人姓名                                                         肖 伟
    主管会计工作负责人姓名                                                 陈友龙
    会计机构负责人(会计主管人员)姓名                                     焦晓杉
    公司负责人肖伟、主管会计工作负责人陈友龙及会计机构负责人(会计主管人员)焦晓杉声明:保证本季度报告中财务报告的真实、完整。§2 公司基本情况
    2.1 主要会计数据及财务指标
                                                                                       币种:人民币
                                                                                 本报告期末比上年
                                          本报告期末            上年度期末
                                                                                   度期末增减(%)
    总资产(元)                             2,910,343,814.13      2,581,406,604.69                12.74
    所有者权益(或股东权益)(元)           1,555,872,963.63      1,435,872,808.83                 8.36归属于上市公司股东的每股净资产
                                                     3.74                3.39                  10.32(元/股)
                                                 年初至报告期期末                     比上年同
                                                   (1-9 月)                        期增减(%)
    经营活动产生的现金流量净额(元)                               95,487,797.42                   不适用每股经营活动产生的现金流量净额
                                                                         0.23                 不适用(元/股)
                                            报告期           年初至报告期期末      本报告期比上
                                          (7-9 月)           (1-9 月)        年同期增减(%)
    归属于上市公司股东的净利润(元)            80,951,180.44        184,420,738.63                22.58
    基本每股收益(元/股)                              0.19                  0.44                18.75扣除非经常性损益后的基本每股收
                                                     0.18                0.46                  38.46益(元/股)
    稀释每股收益(元/股)                                 0.19               0.44                  18.75
    加权平均净资产收益率(%)                            5.48%             12.22%    增加 0.16 个百分点扣除非经常性损益后的加权平均净
                                                     5.03%             12.76%    增加 0.77 个百分点资产收益率(%)
    扣除非经常性损益项目和金额:
                                                                             单位:元 币种:人民币
                                                                       年初至报告期期末金额
                            项   目
                                                                           (1-9 月)
    非流动资产处置损益                                                                   -272,958.52计入当期损益的政府补助,但与公司正常经营业务密切相关,
    符合国家政策规定、按照一定标准定额或定量持续享受的政府                                14,502,675.08补助除外
    除上述各项之外的其他营业外收入和支出                                                -23,821,742.44
      江苏康缘药业股份有限公司(股票代码:600557)                          2012 年第三季度报告
    所得税影响额                                                                      1,418,144.97
    少数股东权益影响额(税后)                                                            9,616.42
                        合       计                                              -8,164,264.49
    2.2 报告期末股东总人数及前十名无限售条件股东持股情况表
                                                                                        单位:股
    报告期末股东总数(户)                                                                    12,681
                          前十名无限售条件流通股股东持股情况
                                                        期末持有无限售条
                  股东名称(全称)                                                     种   类
                                                          件流通股的数量
    连云港康贝尔医疗器械有限公司                                    22,132,338         人民币普通股
    肖 伟                                                           11,808,082         人民币普通股
    中国工商银行-汇添富成长焦点股票型证券投资基金                   9,694,130         人民币普通股中国建设银行股份有限公司-泰达宏利市值优选股票型证券
                                                                 9,693,896         人民币普通股投资基金
    中国农业银行-景顺长城内需增长贰号股票型证券投资基金             8,584,456         人民币普通股
    交通银行-华安策略优选股票型证券投资基金                         7,883,881         人民币普通股招商银行股份有限公司-光大保德信优势配置股票型证券投
                                                                 7,500,000         人民币普通股资基金中国工商银行股份有限公司-汇添富医药保健股票型证券投
                                                                 5,300,000         人民币普通股资基金
    中国工商银行-广发聚丰股票型证券投资基金                         5,044,643         人民币普通股
    中国工商银行-建信优化配置混合型证券投资基金                     4,920,346         人民币普通股§3 重要事项
    3.1 公司主要会计报表项目、财务指标大幅度变动的情况及原因
    √适用 □不适用
    3.1.1 截至报告期末,公司资产负债项目大幅变动的原因分析
                                                                           单位:元 币种:人民币
    项     目         2012-9-30           2011-12-31      增减幅度             变动说明
                                                                     主要系报告期内公司购买银行理
    交易性金融资产                            1,000,000.00    -100.00%
                                                                     财产品到期所致
                                                                     主要系报告期内公司项目投入增
    在建工程            321,504,756.11      236,886,084.24      35.72%
                                                                     加所致
                                                                     主要系报告期内公司购买土地所
    无形资产            133,421,087.94      101,349,827.53      31.64%
                                                                     有权及购买新药技术所致
                                                                     主要系报告期内预收货款减少所
    预收款项              10,505,221.44      28,973,348.05     -63.74%
                                                                     致
                                                                     主要系报告期内公司销售收入增
    应交税费              59,933,893.15      21,066,522.58     184.50%
                                                                     长,利润增加所致
                                                                     主要系报告期内公司支付现金红
    应付股利                 446,055.40          852,728.41    -47.69%
                                                                     利款所致
                                                                     主要系报告期内公司收到资本化
    其他流动负债          31,818,907.73      22,976,582.81      38.48%
                                                                     政府补助所致
                                                                     主要系报告期内公司项目贷款增
    长期借款            303,000,000.00      148,000,000.00     104.73%
                                                                     加所致
                                                                     主要系报告期内子公司收到科技
    专项应付款            7,326,346.00        3,278,438.00     123.47%
                                                                     成果转化项目贷款所致
           江苏康缘药业股份有限公司(股票代码:600557)                             2012 年第三季度报告
       3.1.2 年初至报告期期末,公司利润表项目大幅动变动的原因分析
                                                                                   单位:元 币种:人民币
       项    目          2012 年 1-9 月     2011 年 1-9 月      增减幅度             变动说明
                                                                           主要系报告期内公司银行借款增
      财务费用           41,241,956.64        25,799,153.34       59.86%
                                                                           加所致
                                                                           主要系上年同期公司出售子公司
      投资收益                31,557.51          618,264.36      -94.90%
                                                                           股权所致
                                                                           主要系报告期内公司处置非流动
    营业外支出              714,295.06         296,167.36       141.18%   性资产损失以及公益性捐赠增加
                                                                           所致
       3.1.3 年初至报告期期末,公司现金流量表项目大幅动变动的原因分析
                                                                                   单位:元 币种:人民币
        项    目          2012 年 1-9 月       2011 年 1-9 月     增减幅度               变动说明
                                                                               主要系报告期内公司终止股权
    筹资活动产生的
                           70,010,347.02       278,858,931.98       -74.89%    激励支付股权回购款及偿还债
    现金流量净额
                                                                               务所致
       3.2 重大事项进展情况及其影响和解决方案的分析说明
       □适用√不适用
       3.3 公司、股东及实际控制人承诺事项履行情况
       √适用 □不适用
                                                                                        是否有履     是否及时
    承诺背景      承诺类型               承诺方                         承诺内容
                                                                                          行期限     严格履行
                                                          在增持计划实施期间及法定
    与控股股东                                                期限内,累计增持股份不超
    增持相关的    股份限售     江苏康缘集团有限责任公司       过本公司已发行总股本的            是            是
    承诺                                                  1.03%,并不减持其持有的本
                                                          公司股份
       3.4 预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相比发生大幅度变动
    的警示及原因说明
       □适用 √不适用
       3.5 报告期内现金分红政策的执行情况
       本报告期内公司未进行现金分红。
       2012 年 7 月 25 日,根据《公司法》、中国证券监督管理委员会《关于进一步落实上市公司现金
    分红有关事项的通知》(证监发[2012]37 号)和中国证券监督管理委员会江苏监管局《关于进一步落
    实上市公司现金分红有关要求的通知》(苏证监公司字[2012]276 号)的规定,为进一步规范公司行
    为,保护公司及广大投资者利益,促进公司健康、稳定的发展,公司第四届董事会第十八次会议审议
    通过了《关于修改公司章程的议案》,在公司章程中明确规定利润分配政策、利润分配的形式、现金
    分配的条件、股票股利分配的条件、利润分配的决策程序和机制、有关利润分配的信息披露、利润分
    配政策的调整原则及决策程序和机制,进一步完善了公司的利润分配制度和分红决策监督机制。2012
    年 8 月 10 日,公司 2012 年第二次临时股东大会审议通过了该项议案。(详见上海证券交易所网站
    www.sse.com.cn,关于《公司章程修正案的公告》,公告编号:2012-021)
                                                                      江苏康缘药业股份有限公司
                                                                                法定代表人:肖伟
                                                                              2012 年 10 月 25 日
      江苏康缘药业股份有限公司(股票代码:600557)                         2012 年第三季度报告§4 附录
    4.1
                                    合并资产负债表(一)
                                         2012 年 9 月 30 日编制单位: 江苏康缘药业股份有限公司
                                                      单位:元 币种:人民币 审计类型:未经审计
               项   目                          期末余额                   年初余额流动资产:
    货币资金                                         233,682,647.64         201,714,625.85
    交易性金融资产                                                            1,000,000.00
    应收票据                                         457,115,868.56         430,108,396.29
    应收账款                                         781,617,915.40         651,454,027.55
    预付款项                                         223,871,134.78         197,776,217.36
    其他应收款                                        62,395,171.82          48,450,680.85
    买入返售金融资产
    存货                                             71,252,918.64           64,605,037.90
    一年内到期的非流动资产
    其他流动资产
      流动资产合计                              1,829,935,656.84          1,595,108,985.80非流动资产:
    长期应收款
    长期股权投资                                       3,983,029.67            3,997,631.06
    投资性房地产
    固定资产                                         537,632,575.80         560,670,864.24
    在建工程                                         321,504,756.11         236,886,084.24
    工程物资
    固定资产清理
    生产性生物资产
    油气资产
    无形资产                                         133,421,087.94         101,349,827.53
    开发支出                                          20,600,000.00          20,600,000.00
    商誉                                              58,988,858.14          58,988,858.14
    长期待摊费用                                         445,921.61             445,921.61
    递延所得税资产                                     3,831,928.02           3,358,432.07
    其他非流动资产
      非流动资产合计                            1,080,408,157.29            986,297,618.89
           资产总计                             2,910,343,814.13          2,581,406,604.69
    公司法定代表人: 肖伟                 主管会计工作负责人:陈友龙          会计机构负责人:焦晓杉
      江苏康缘药业股份有限公司(股票代码:600557)                        2012 年第三季度报告
                                    合并资产负债表(二)
                                         2012 年 9 月 30 日编制单位: 江苏康缘药业股份有限公司
                                                     单位:元 币种:人民币 审计类型:未经审计
               项   目                           期末余额                  年初余额流动负债:
    短期借款                                           452,000,000.00         466,420,000.00
    应付票据                                           120,000,000.00         120,000,000.00
    应付账款                                           117,477,284.13         126,301,409.26
    预收款项                                            10,505,221.44          28,973,348.05
    卖出回购金融资产款
    应付职工薪酬                                         6,682,491.42           6,318,701.55
    应交税费                                            59,933,893.15          21,066,522.58
    应付利息                                             1,068,300.45           1,036,726.43
    应付股利                                               446,055.40             852,728.41
    其他应付款                                         203,171,622.28         161,354,504.69
    其他流动负债                                        31,818,907.73          22,976,582.81
      流动负债合计                                   1,003,103,776.00         955,300,523.78非流动负债:
    长期借款                                           303,000,000.00         148,000,000.00
    专项应付款                                           7,326,346.00           3,278,438.00
    预计负债
    递延所得税负债
    其他非流动负债
      非流动负债合计                                   310,326,346.00         151,278,438.00
        负债合计                                     1,313,430,122.00       1,106,578,961.78所有者权益(或股东权益):
    实收资本(或股本)                                 415,646,691.00         423,246,691.00
    资本公积                                           268,152,669.08         300,041,256.29
    减:库存股
    专项储备
    盈余公积                                           117,993,352.67         117,993,352.67
    一般风险准备
    未分配利润                                         754,846,602.44         595,364,665.27
    外币报表折算差额                                      -766,351.56            -773,156.40
    归属于母公司所有者权益合计                       1,555,872,963.63       1,435,872,808.83
    少数股东权益                                        41,040,728.50          38,954,834.08
           所有者权益合计                            1,596,913,692.13       1,474,827,642.91
        负债和所有者权益总计                         2,910,343,814.13       2,581,406,604.69
    公司法定代表人: 肖伟                 主管会计工作负责人:陈友龙          会计机构负责人:焦晓杉
      江苏康缘药业股份有限公司(股票代码:600557)                         2012 年第三季度报告
                                   母公司资产负债表(一)
                                         2012 年 9 月 30 日编制单位: 江苏康缘药业股份有限公司
                                                         单位:元 币种:人民币 审计类型:未经审计
               项   目                           期末余额                    年初余额流动资产:
    货币资金                                           192,375,314.85          146,727,209.10
    交易性金融资产                                                               1,000,000.00
    应收票据                                           412,690,188.58          381,907,832.38
    应收账款                                           676,954,753.54          553,986,029.41
    预付款项                                           163,868,094.34          141,229,785.61
    其他应收款                                          19,715,207.95           15,658,131.83
    存货                                                58,734,526.96           47,214,394.83
    其他流动资产
      流动资产合计                                   1,524,338,086.22        1,287,723,383.16非流动资产:
    长期应收款
    长期股权投资                                       190,859,225.34          190,873,826.73
    投资性房地产
    固定资产                                           503,110,878.59          525,756,892.44
    在建工程                                           179,962,806.17          155,726,938.31
    工程物资
    固定资产清理
    生产性生物资产
    油气资产
    无形资产                                            81,686,168.63           76,785,428.36
    开发支出                                            20,600,000.00           20,600,000.00
    商誉
    长期待摊费用
    递延所得税资产                                       1,904,185.24             1,591,569.12
    其他非流动资产
      非流动资产合计                                   978,123,263.97          971,334,654.96
         资产总计                                    2,502,461,350.19        2,259,058,038.12
    公司法定代表人: 肖伟                 主管会计工作负责人:陈友龙          会计机构负责人:焦晓杉
      江苏康缘药业股份有限公司(股票代码:600557)                         2012 年第三季度报告
                                   母公司资产负债表(二)
                                         2012 年 9 月 30 日编制单位: 江苏康缘药业股份有限公司
                                                         单位:元 币种:人民币 审计类型:未经审计
               项   目                           期末余额                    年初余额流动负债:
    短期借款                                           302,000,000.00          367,000,000.00
    交易性金融负债
    应付票据                                           100,000,000.00          100,000,000.00
    应付账款                                            91,589,542.60           97,827,270.17
    预收款项                                             8,935,897.08           26,375,303.30
    应付职工薪酬                                         4,614,121.38            4,347,931.37
    应交税费                                            52,677,048.19           12,447,574.98
    应付利息                                               793,027.78              873,767.28
    应付股利
    其他应付款                                        125,449,211.63           121,764,489.53
    其他流动负债                                       31,818,907.73            22,976,582.81
      流动负债合计                                    717,877,756.39           753,612,919.44非流动负债:
    长期借款                                           243,000,000.00           78,000,000.00
    应付债券
    长期应付款
    专项应付款                                           3,026,346.00             3,278,438.00
    预计负债
    递延所得税负债
    其他非流动负债
      非流动负债合计                                  246,026,346.00            81,278,438.00
        负债合计                                      963,904,102.39           834,891,357.44所有者权益(或股东权益):
    实收资本(或股本)                                 415,646,691.00          423,246,691.00
    资本公积                                           268,152,669.08          300,041,256.29
    减:库存股
    专项储备
    盈余公积                                           116,186,192.11          116,186,192.11
    一般风险准备
    未分配利润                                         738,571,695.61          584,692,541.28
    所有者权益(或股东权益)合计                         1,538,557,247.80        1,424,166,680.68
    负债和所有者权益总计                                 2,502,461,350.19        2,259,058,038.12
    公司法定代表人: 肖伟                 主管会计工作负责人:陈友龙          会计机构负责人:焦晓杉
      江苏康缘药业股份有限公司(股票代码:600557)                             2012 年第三季度报告
    4.2
                                             合并利润表编制单位: 江苏康缘药业股份有限公司
                                                         单位:元 币种:人民币 审计类型:未经审计
                              本期金额           上期金额           年初至报告期     上年年初至报告期
          项目
                            (7-9 月)        (7-9 月)        期末金额(1-9 月) 期末金额(1-9 月)
    一、营业总收入            530,817,908.46      421,861,306.87      1,364,701,390.59   1,158,410,142.14
    其中:营业收入            530,817,908.46      421,861,306.87      1,364,701,390.59   1,158,410,142.14
    二、营业总成本            442,280,663.97      358,662,010.69      1,159,877,271.60     983,881,931.08
    其中:营业成本            154,445,769.85      105,005,515.65        338,654,829.45     329,167,481.16
    营业税金及附加          8,741,173.33        7,228,027.22         22,856,026.78      18,107,275.99
    销售费用              225,691,429.20      176,336,155.47        570,449,854.49     457,865,766.75
    管理费用               37,364,838.61       61,606,486.33        184,378,252.08    150,253,149.47
    财务费用               15,257,848.39        7,723,880.63         41,241,956.64      25,799,153.34
    资产减值损失              779,604.59          761,945.39          2,296,352.16       2,689,104.37
    投资收益                  -18,137.52          613,108.03             31,557.51         618,264.36
    三、营业利润               88,519,106.97       63,812,404.21        204,855,676.50     175,146,475.42
    加:营业外收入          7,882,398.42       15,040,816.12         14,941,681.97      20,772,518.52
    减:营业外支出             55,724.81          232,612.04            714,295.06         296,167.36
    四、利润总额               96,345,780.58       78,620,608.29        219,083,063.41     195,622,826.58
    减:所得税费用         14,505,899.64       11,949,128.67         32,576,430.36      29,586,837.18
    五、净利润                 81,839,880.94       66,671,479.62        186,506,633.05     166,035,989.40
    归属于母公司所有
                           80,951,180.44       66,038,320.38        184,420,738.63     162,753,751.62者的净利润
    少数股东损益               888,700.50            633,159.24       2,085,894.42       3,282,237.78六、每股收益:
    (一)基本每股收益                  0.19                 0.16               0.44                   0.39
    (二)稀释每股收益                  0.19                 0.16               0.44                   0.39七、其他综合收益
    八、综合收益总额           81,839,880.94       66,671,479.62        186,506,633.05     166,035,989.40归属于母公司所有者的
                           80,951,180.44       66,038,320.38        184,420,738.63     162,753,751.62综合收益总额归属于少数股东的综合
                               888,700.50            633,159.24       2,085,894.42       3,282,237.78收益总额
    公司法定代表人: 肖伟                 主管会计工作负责人:陈友龙               会计机构负责人:焦晓杉
      江苏康缘药业股份有限公司(股票代码:600557)                         2012 年第三季度报告
                                          母公司利润表编制单位: 江苏康缘药业股份有限公司
                                                       单位:元 币种:人民币 审计类型:未经审计
                              本期金额           上期金额      年初至报告期期末 上年年初至报告期
         项目
                            (7-9 月)        (7-9 月)       金额(1-9 月)  期末金额(1-9 月)
    一、营业收入              424,665,443.36     349,619,468.44 1,125,645,093.17         908,819,371.70
    减:营业成本          116,828,113.30      87,895,872.82       289,506,650.43     253,905,533.70
    营业税金及附加          7,264,149.86       6,019,498.28        18,763,802.58      14,524,066.55
    销售费用              173,148,611.65     136,754,902.56       431,953,753.68     338,441,564.81
    管理费用               27,732,364.75      50,428,162.87       153,073,091.63     114,128,899.14
    财务费用               13,290,401.34       6,402,309.97        34,413,155.35      21,479,164.12
    资产减值损失                777,358.27         779,227.38       2,076,709.64       2,037,644.29
    投资收益                    -18,137.52     5,320,645.17            31,557.51       9,118,401.50
    二、营业利润               85,606,306.67      66,660,139.73       195,889,487.37     173,420,900.59
    加:营业外收入          7,623,028.66      14,940,816.12        14,616,545.38      18,489,310.82
    减:营业外支出                1,500.00         176,940.76         499,750.78         232,329.01
    三、利润总额               93,227,835.33      81,424,015.09       210,006,281.97     191,677,882.40
    减:所得税费用         13,866,217.24      11,439,411.32        31,188,326.18      27,660,007.72
    四、净利润                 79,361,618.09      69,984,603.77       178,817,955.79     164,017,874.68五、每股收益:
    (一)基本每股收益
    (二)稀释每股收益六、其他综合收益
    七、综合收益总额           79,361,618.09       69,984,603.77     178,817,955.79     164,017,874.68
    公司法定代表人: 肖伟                 主管会计工作负责人:陈友龙           会计机构负责人:焦晓杉
      江苏康缘药业股份有限公司(股票代码:600557)                         2012 年第三季度报告4.3
                                        合并现金流量表
                                          2012 年 1—9 月编制单位: 江苏康缘药业股份有限公司
                                                      单位:元 币种:人民币 审计类型:未经审计
                                                  年初至报告期             上年年初至报告期
                 项   目
                                                期末金额(1-9 月)         期末金额(1-9 月)一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金                      1,406,664,278.45            969,681,808.85
    收到的税费返还                                          240,000.00              4,746,913.71
    收到其他与经营活动有关的现金                         79,878,621.44             64,596,078.80
      经营活动现金流入小计                            1,486,782,899.89          1,039,024,801.36
    购买商品、接受劳务支付的现金                        286,810,186.28            226,781,332.03
    支付给职工以及为职工支付的现金                      215,829,209.64            196,896,835.37
    支付的各项税费                                      226,368,537.13            205,424,210.08
    支付其他与经营活动有关的现金                        662,287,169.42            442,515,992.91
      经营活动现金流出小计                            1,391,295,102.47          1,071,618,370.39
        经营活动产生的现金流量净额                       95,487,797.42            -32,593,569.03二、投资活动产生的现金流量:
    收回投资收到的现金                                    1,000,000.00                       -0.08
    取得投资收益收到的现金                                   46,158.90
    处置固定资产、无形资产和其他长期
                                                         32,892,155.00                 338,053.05资产收回的现金净额
    处置子公司及其他营业单位收到的
                                                                                    -1,567,042.64现金净额
    收到其他与投资活动有关的现金                          4,300,000.00
      投资活动现金流入小计                               38,238,313.90             -1,228,989.67
    购建固定资产、无形资产和其他长期
                                                        171,774,421.92            237,154,436.54资产支付的现金
    投资支付的现金                                                                  5,000,000.00
      投资活动现金流出小计                             171,774,421.92             242,154,436.54
        投资活动产生的现金流量净额                    -133,536,108.02            -243,383,426.21三、筹资活动产生的现金流量:
    吸收投资收到的现金                                 -63,308,000.00              63,308,000.00
    取得借款收到的现金                                 660,500,000.00             502,722,872.50
    收到其他与筹资活动有关的现金                        43,000,000.00              18,019,804.11
      筹资活动现金流入小计                             640,192,000.00             584,050,676.61
    偿还债务支付的现金                                 512,420,000.00             247,206,240.72
    分配股利、利润或偿付利息支付的现金                    57,761,652.98              39,385,503.91
    支付其他与筹资活动有关的现金                                                   18,600,000.00
      筹资活动现金流出小计                             570,181,652.98             305,191,744.63
        筹资活动产生的现金流量净额                      70,010,347.02             278,858,931.98
    四、汇率变动对现金及现金等价物的影响                         5,985.37                -131,044.94
    五、现金及现金等价物净增加额                            31,968,021.79               2,750,891.80
    加:期初现金及现金等价物余额                       201,714,625.85             151,523,396.75
    六、期末现金及现金等价物余额                           233,682,647.64             154,274,288.55
    公司法定代表人: 肖伟                 主管会计工作负责人:陈友龙           会计机构负责人:焦晓杉
      江苏康缘药业股份有限公司(股票代码:600557)                             2012 年第三季度报告
                                       母公司现金流量表
                                          2012 年 1—9 月编制单位: 江苏康缘药业股份有限公司
                                                          单位:元 币种:人民币 审计类型:未经审计
                                                        年初至报告期         上年年初至报告期
                     项   目
                                                      期末金额(1-9 月)   期末金额(1-9 月)一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金                        1,140,283,543.95           732,577,553.96
    收到其他与经营活动有关的现金                           66,433,760.97            31,465,674.16
      经营活动现金流入小计                              1,206,717,304.92           764,043,228.12
    购买商品、接受劳务支付的现金                          236,107,014.81           166,991,540.51
    支付给职工以及为职工支付的现金                        167,878,663.98           149,302,436.03
    支付的各项税费                                        183,587,530.79           165,856,727.63
    支付其他与经营活动有关的现金                          484,765,424.27           296,183,794.49
      经营活动现金流出小计                              1,072,338,633.85           778,334,498.66
         经营活动产生的现金流量净额                       134,378,671.07           -14,291,270.54二、投资活动产生的现金流量:
    收回投资收到的现金                                        1,000,000.00
    取得投资收益收到的现金                                       46,158.90            3,792,500.00
    处置固定资产、无形资产和其他长期资产收
                                                             32,892,155.00              338,053.05回的现金净额
      投资活动现金流入小计                                   33,938,313.90            4,130,553.05
    购建固定资产、无形资产和其他长期资产支
                                                            112,160,818.96         184,240,503.06付的现金
    投资支付的现金                                                                   25,000,000.00
    支付其他与投资活动有关的现金
      投资活动现金流出小计                                  112,160,818.96         209,240,503.06
         投资活动产生的现金流量净额                         -78,222,505.06        -205,109,950.01三、筹资活动产生的现金流量:
    吸收投资收到的现金                                      -63,308,000.00          63,308,000.00
    取得借款收到的现金                                      493,000,000.00         384,000,000.00
      筹资活动现金流入小计                                  429,692,000.00         447,308,000.00
    偿还债务支付的现金                                      393,000,000.00         191,000,000.00
    分配股利、利润或偿付利息支付的现金                       47,200,060.26          37,268,454.14
    支付其他与筹资活动有关的现金
      筹资活动现金流出小计                                  440,200,060.26         228,268,454.14
         筹资活动产生的现金流量净额                         -10,508,060.26         219,039,545.86四、汇率变动对现金及现金等价物的影响
    五、现金及现金等价物净增加额                                 45,648,105.75            -361,674.69
    加:期初现金及现金等价物余额                            146,727,209.10         106,838,320.05
    六、期末现金及现金等价物余额                                192,375,314.85         106,476,645.36
    公司法定代表人: 肖伟                 主管会计工作负责人:陈友龙               会计机构负责人:焦晓杉